» Articles » PMID: 20357097

Autologous Neutralizing Antibodies to the Transmitted/founder Viruses Emerge Late After Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys

Abstract

While the simian immunodeficiency virus (SIV)-infected rhesus monkey is an important animal model for human immunodeficiency virus type 1 (HIV-1) infection of humans, much remains to be learned about the evolution of the humoral immune response in this model. In HIV-1 infection, autologous neutralizing antibodies emerge 2 to 3 months after infection. However, the ontogeny of the SIV-specific neutralizing antibody response in mucosally infected animals has not been defined. We characterized the kinetics of the autologous neutralizing antibody response to the transmitted/founder SIVmac251 using a pseudovirion-based TZM-bl cell assay and monitored env sequence evolution using single-genome amplification in four rhesus animals that were infected via intrarectal inoculations. We show that the SIVmac251 founder viruses induced neutralizing antibodies at 5 to 8 months after infection. Despite their slow emergence and low titers, these neutralizing antibodies selected for escape mutants that harbored substitutions and deletions in variable region 1 (V1), V2, and V4 of Env. The neutralizing antibody response was initially focused on V4 at 5 to 8 months after infection and then targeted V1/V2 and V4 by 16 months. These findings reveal a striking delay in the development of neutralizing antibodies in SIVmac-infected animals, thus raising questions concerning the suitability of SIVmac251 as a challenge strain to screen AIDS vaccines that elicit neutralizing antibodies as a means to prevent virus acquisition. They also illustrate the capacity of the SIVmac quasispecies to modify antigenic determinants in response to very modest titers of neutralizing antibodies.

Citing Articles

Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants.

Fray E, Wu F, Simonetti F, Zitzmann C, Sambaturu N, Molina-Paris C Cell Host Microbe. 2023; 31(3):356-372.e5.

PMID: 36809762 PMC: 10583177. DOI: 10.1016/j.chom.2023.01.016.


Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth.

Wang X, Vincent E, Siddiqui S, Turnbull K, Lu H, Blair R Nat Commun. 2022; 13(1):4823.

PMID: 35973985 PMC: 9381774. DOI: 10.1038/s41467-022-32554-z.


SIV infection duration largely determines broadening of neutralizing antibody response in macaques.

Wu F, Ourmanov I, Kirmaier A, Leviyang S, LaBranche C, Huang J J Clin Invest. 2020; 130(10):5413-5424.

PMID: 32663192 PMC: 7524488. DOI: 10.1172/JCI139123.


The -HIV syndemic interaction: why treating infection may be crucial for HIV-1 eradication.

Waters R, Ndengane M, Abrahams M, Diedrich C, Wilkinson R, Coussens A Future Virol. 2020; 15(2):101-125.

PMID: 32273900 PMC: 7132588. DOI: 10.2217/fvl-2019-0069.


High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.

Ita S, Hill A, Lam E, Dufort F, Yang X, Newman R J Virol. 2018; 92(7).

PMID: 29343575 PMC: 5972902. DOI: 10.1128/JVI.01574-17.


References
1.
Rong R, Gnanakaran S, Decker J, Bibollet-Ruche F, Taylor J, Sfakianos J . Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J Virol. 2007; 81(11):5658-68. PMC: 1900276. DOI: 10.1128/JVI.00257-07. View

2.
Kang S, Quan F, Huang C, Guo L, Ye L, Yang C . Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology. 2004; 331(1):20-32. DOI: 10.1016/j.virol.2004.10.005. View

3.
Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C . Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science. 2007; 315(5818):1583-6. DOI: 10.1126/science.1131528. View

4.
Ogert R, Lee M, Ross W, Buckler-White A, Martin M, Cho M . N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J Virol. 2001; 75(13):5998-6006. PMC: 114315. DOI: 10.1128/JVI.75.13.5998-6006.2001. View

5.
Liu J, Bartesaghi A, Borgnia M, Sapiro G, Subramaniam S . Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008; 455(7209):109-13. PMC: 2610422. DOI: 10.1038/nature07159. View